Showing results (231-240 of 241) with videos related to
Sort By:
Pageof 25
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2015
TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast CancerSteven J Isakoff, Erica L Mayer, Lei He, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 30, 2013
Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trialPaul E Goss, James N Ingle, Kathleen I Pritchard, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 27, 2020
Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor αJames N Ingle, Junmei Cairns, Vera J Suman, et al.Breast Cancer Research and Treatment|June 23, 2025
Adjunctive statistical standardization of quantitated adjuvant HER2 and ultra-low HER2 in Canadian Cancer Trials Group MA.27 trial of exemestane versus anastrozoleJudith-Anne W Chapman, Jane Bayani, Sandip SenGupta, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2024
Adjunctive Statistical Standardization of Adjuvant Estrogen Receptor and Progesterone Receptor in Canadian Cancer Trials Group MA.27 Postmenopausal Breast Cancer Trial of Exemestane Versus AnastrozoleJudith-Anne W Chapman, Jane Bayani, Sandip SenGupta, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 9, 2014
Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancerElizabeth Maunsell, Paul E Goss, Rowan T Chlebowski, et al.The Oncologist|November 19, 2020
Patient Navigation to Improve Early Access to Supportive Care for Patients with Advanced Cancer in Resource-Limited Settings: A Randomized Controlled TrialEnrique Soto-Perez-de-Celis, Yanin Chavarri-Guerra, Wendy Alicia Ramos-Lopez, et al.Cancer Discovery|December 16, 2017
Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor-Positive Breast CancerKarina J Matissek, Maristela L Onozato, Sheng Sun, et al.The Lancet. Oncology|November 3, 2015
Progress and remaining challenges for cancer control in Latin America and the CaribbeanKathrin Strasser-Weippl, Yanin Chavarri-Guerra, Cynthia Villarreal-Garza, et al.The Lancet. Oncology|April 16, 2014
Challenges to effective cancer control in China, India, and RussiaPaul E Goss, Kathrin Strasser-Weippl, Brittany L Lee-Bychkovsky, et al.Pageof 25